Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2 Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant
In conclusion, nucleocapsid antibody provides instructive clues about the immunogenicity of nucleocapsid proteins by different seroconversion rates and titers according to the severity of infection, host immune status, and different variants of concern.PMID:37724496 | DOI:10.3346/jkms.2023.38.e292
Source: J Korean Med Sci - Category: General Medicine Authors: Beomki Lee Jae-Hoon Ko Jin Yang Baek Haein Kim Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Eun-Suk Kang Source Type: research
More News: Allergy & Immunology | Coronavirus | Covid Vaccine | COVID-19 | General Medicine | Respiratory Medicine | SARS | Study | Vaccines